Please provide your email address to receive an email when new articles are posted on . The Foundation to Advance Vascular Cures has launched a new virtual educational resource directed at medical ...
The European Commission (EC) has approved a regimen of rivaroxaban (Xarelto, Bayer) 2.5 mg twice daily plus acetylsalicylic acid (ASA) 75 to 100 mg once daily for the prevention of atherothrombotic ...
“Diabetes and pre-diabetes are associated with increased risk of atherosclerotic cardiovascular disease (ASCVD), defined as coronary heart disease, cerebrovascular disease, or PAD,” notes Dr. Helena ...
Smoking adversely affects cardiovascular risk factors, affects inflammation, and is linked with atherosclerosis, but whether the smoking-atherosclerosis relationship is mediated through traditional ...
Johnson & Johnson and Bayer’s wide-spanning VOYAGER PAD study continues to be a gold mine for proving its Xarelto’s worth in several subsets of patients with peripheral artery disease (PAD). New ...
COMPASS open label extension study results support the long-term use of XARELTO ® plus aspirin for vascular protection in patients with chronic CAD and/or PAD XATOA registry provides further evidence ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results